Moderna shares are trading higher as traders circulate the posting of Merck's new Phase 2/3 trial of pembrolizumab (Keytryuda) plus Moderna's V940 in cutaneous squamous cell carcinoma on clinicaltrials.gov on March 6. Also, Jefferies says this third study suggests more investment and confidence for the program.
Portfolio Pulse from Benzinga Newsdesk
Moderna shares are trading higher following the announcement of a new Phase 2/3 trial of pembrolizumab (Keytruda) by Merck in combination with Moderna's V940 for cutaneous squamous cell carcinoma. The trial's posting on clinicaltrials.gov and Jefferies' positive outlook on the program's investment and confidence have contributed to the optimism.

March 11, 2024 | 6:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Moderna's stock is experiencing an uptick due to the positive news regarding the new Phase 2/3 trial in collaboration with Merck, indicating increased confidence and investment in their program.
The announcement of the trial and the positive commentary from Jefferies likely lead to increased investor confidence in Moderna's pipeline and its collaboration with Merck, potentially driving the stock price up in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90